News Madrigal Pharmaceuticals Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™ Staff June 25, 2022 Iframe sync Post navigation Previous: Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B ProgramNext: Pfizer and BioNTech Announce Omicron-Adapted COVID-19 Vaccine Candidates Demonstrate High Immune Response Against Omicron More Stories Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025 Healthcare News Pharmaceutical Queue Ventures Announces Closing of Brokered Private Placement of Subscription Receipts of Custom Fundco Inc. Staff December 5, 2025 Coronavirus COVID-19 News Patient Care Predictmedix AI Announces Closing of Final Tranche of Non-Brokered Private Placement Staff December 5, 2025
